Assorted news from the last week:
Children with birth defects who were conceived via in vitro fertilization (IVF) were more likely to develop childhood cancer compared to those conceived naturally, according to the results of a cohort study originating at Michigan State University.
The insurance dropout rate among adolescents and young adult cancer survivors may have been lowered due to the dependent coverage provision in the Affordable Care Act, according to the findings of a new study out of UCSF Benioff Children’s Hospital.
Lack of transportation options and falling blood supplies during the pandemic have complicated pediatric cancer treatment in the Phillipines.
Keep up with the happenings at ACCELERATE, an international multi-stakeholder organization working to speed drug development for children and adolescents with cancer.
Upcoming webinars and Online Opportunities:
Neuroblastoma Parent Global Symposium on November 6th and 7th, 2020 offers a free, online, 2-day event that will bring together families directly affected by neuroblastoma around the world with those who work to treat, help and support them. Researchers and clinicians will lead sessions to provide information on current treatments around the world and share emerging therapies. Registration is now open to reserve a space for this free event!
CAC2 hosts leaders of the New Approaches to Neuroblastoma Therapy (NANT) consortium about the progress and challenges associated with developing new strategies for refractory and relapsed neuroblastoma patients. Learn about the history of this 20 year-old, multi-institution network, their collaborations with the Children’s Oncology Group and other partners, current clinical trials and plans for future studies.
View the recent webinar hosted by Children’s Cancer Cause: “Elevating the Needs of Childhood Cancer Survivors” featuring Dr. Maria Monica Gramatges, Co-Director of the Texas Children’s Long-Term Survivor Program, and Emily S. Tonorezos, MD, MPH, newly appointed Director of the Office of Cancer Survivorship at the NCI.